{"id":435242,"date":"2021-02-12T13:57:07","date_gmt":"2021-02-12T18:57:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=435242"},"modified":"2021-02-12T13:57:07","modified_gmt":"2021-02-12T18:57:07","slug":"canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/","title":{"rendered":"Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine<\/b><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nModerna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Canadian Government has increased its confirmed order commitment by 4 million doses of the COVID-19 Vaccine Moderna bringing its confirmed order commitment to 44 million doses. This increase reflects continued efforts by the Canadian Government to secure access to safe and effective COVID-19 vaccines for Canadian citizens.\n<\/p>\n<p>\n\u201cWe appreciate our collaboration with the Canadian government as we seek to defeat the pandemic with our vaccine. Today\u2019s increased supply agreement from the Canadian government reaffirms the confidence in Moderna\u2019s COVID-19 vaccine,\u201d said Stephane Bancel, Chief Executive Officer of Moderna.\n<\/p>\n<p>\nOn December 23, Health Canada <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.modernatx.com%2Fnews-releases%2Fnews-release-details%2Fhealth-canada-authorizes-moderna-covid-19-vaccine-canada&amp;esheet=52378657&amp;newsitemid=20210212005486&amp;lan=en-US&amp;anchor=authorized&amp;index=1&amp;md5=44efa02892a43c70fbc0fd847dfb791e\">authorized<\/a> the COVID-19 Vaccine Moderna for the immunization of people 18 years of age and older under an Interim Order.\n<\/p>\n<p><b>Authorized Use<\/b><\/p>\n<p>\nModerna COVID-19 Vaccine (mRNA-1273 SARS-CoV-2 vaccine) is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in individuals 18 years of age and older.\n<\/p>\n<p><b>About Moderna<\/b><\/p>\n<p>\nModerna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body\u2019s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company\u2019s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.\n<\/p>\n<p>\nHeadquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck &amp; Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and BARDA. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.modernatx.com&amp;esheet=52378657&amp;newsitemid=20210212005486&amp;lan=en-US&amp;anchor=www.modernatx.com&amp;index=2&amp;md5=f3741e4c6519b2ae9b2dd2918d4c3319\">www.modernatx.com<\/a>.\n<\/p>\n<p><b>Forward Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company\u2019s supply and distribution of the Moderna COVID-19 Vaccine to the Canadian Government. In some cases, forward-looking statements can be identified by terminology such as \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201ccould\u201d, \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna\u2019s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the safety, tolerability and efficacy profile of the Moderna COVID-19 Vaccine observed to date may change adversely in ongoing analyses of trial data or subsequent to commercialization; despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Company\u2019s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; Moderna may encounter delays in meeting manufacturing or supply timelines or disruptions in its distribution plans for the Moderna COVID-19 Vaccine; whether and when any biologics license applications and\/or emergency use authorization applications may be filed and ultimately approved by regulatory authorities; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading \u201cRisk Factors\u201d in Moderna\u2019s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=52378657&amp;newsitemid=20210212005486&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=cc25ba786dadf55afb5e079e101e6858\">www.sec.gov<\/a>. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna\u2019s current expectations and speak only as of the date hereof.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210212005486r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210212005486\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210212005486\/en\/<\/a><\/span><\/p>\n<p><b>Canadian Media Enquiries<br \/>\n<\/b><\/p>\n<p>Paul Monlezun<br \/>\n<br \/>+1 613-222-7184<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:paul.monlezun@publicaffairsadvisors.com\">paul.monlezun@publicaffairsadvisors.com<br \/>\n<\/a><\/p>\n<p><b>Moderna Contacts:<br \/>\n<\/b><\/p>\n<p><b>Media:<br \/>\n<\/b><br \/>Colleen Hussey<br \/>\n<br \/>Director, Corporate Communications<br \/>\n<br \/>617-335-1374<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Colleen.Hussey@modernatx.com\">Colleen.Hussey@modernatx.com<br \/>\n<\/a><\/p>\n<p><b>Investors:<br \/>\n<\/b><br \/>Lavina Talukdar<br \/>\n<br \/>Senior Vice President &amp; Head of Investor Relations<br \/>\n<br \/>617-209-5834<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Lavina.Talukdar@modernatx.com\">Lavina.Talukdar@modernatx.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research General Health Pharmaceutical Infectious Diseases Hospitals Genetics Clinical Trials Science Biotechnology Medical Supplies FDA Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210212005486\/en\/858973\/3\/KO_LOGO.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Canadian Government has increased its confirmed order commitment by 4 million doses of the COVID-19 Vaccine Moderna bringing its confirmed order commitment to 44 million doses. This increase reflects continued efforts by the Canadian Government to secure access to safe and effective COVID-19 vaccines for Canadian citizens. \u201cWe appreciate our collaboration with the Canadian government as we seek to defeat the pandemic with our vaccine. Today\u2019s increased supply agreement from the Canadian government reaffirms the confidence in Moderna\u2019s COVID-19 vaccine,\u201d said Stephane Bancel, Chief Executive Officer of Moderna. On &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-435242","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Canadian Government has increased its confirmed order commitment by 4 million doses of the COVID-19 Vaccine Moderna bringing its confirmed order commitment to 44 million doses. This increase reflects continued efforts by the Canadian Government to secure access to safe and effective COVID-19 vaccines for Canadian citizens. \u201cWe appreciate our collaboration with the Canadian government as we seek to defeat the pandemic with our vaccine. Today\u2019s increased supply agreement from the Canadian government reaffirms the confidence in Moderna\u2019s COVID-19 vaccine,\u201d said Stephane Bancel, Chief Executive Officer of Moderna. On &hellip; Continue reading &quot;Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-12T18:57:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210212005486r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine\",\"datePublished\":\"2021-02-12T18:57:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\\\/\"},\"wordCount\":885,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210212005486r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\\\/\",\"name\":\"Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210212005486r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-02-12T18:57:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210212005486r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210212005486r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/","og_locale":"en_US","og_type":"article","og_title":"Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine - Market Newsdesk","og_description":"Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Canadian Government has increased its confirmed order commitment by 4 million doses of the COVID-19 Vaccine Moderna bringing its confirmed order commitment to 44 million doses. This increase reflects continued efforts by the Canadian Government to secure access to safe and effective COVID-19 vaccines for Canadian citizens. \u201cWe appreciate our collaboration with the Canadian government as we seek to defeat the pandemic with our vaccine. Today\u2019s increased supply agreement from the Canadian government reaffirms the confidence in Moderna\u2019s COVID-19 vaccine,\u201d said Stephane Bancel, Chief Executive Officer of Moderna. On &hellip; Continue reading \"Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-12T18:57:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210212005486r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine","datePublished":"2021-02-12T18:57:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/"},"wordCount":885,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210212005486r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/","name":"Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210212005486r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-02-12T18:57:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210212005486r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210212005486r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/canada-purchases-additional-4-million-doses-of-modernas-covid-19-vaccine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Canada Purchases Additional 4 Million Doses of Moderna\u2019s COVID-19 Vaccine"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/435242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=435242"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/435242\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=435242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=435242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=435242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}